Skip to main content

Table 2 Multivariate analysis of risk factors for EBV and CMV infections

From: Two dose levels of rabbit antithymocyte globulin as graft-versus-host disease prophylaxis in haploidentical stem cell transplantation: a multicenter randomized study

Risk factors EBV DNAemia EBV-associated disease CMV DNAemia CMV-associated diseases
HR(95%CI) P HR, 95%CI P HR, 95%CI P HR, 95%CI P
Patient gender
 Male 1 0.084 1 0.110 1 0.140 1 0.560
 Female 0.70 (0.47–1.05)   0.35(0.10–1.26)   1.18 (0.95–1.48)   0.71 (0.23–2.23)  
Patient age
< 27 years 1 0.570 1 0.300 1 0.003 1 0.470
 ≥ 27 years 0.90 (0.63–1.29)   1.58,(0.67–3.74)   1.39 (1.11–1.73)   0.69 (0.24–1.93)  
Conditioning
 BuCy 1 0.005 1 0.061 1 0.380 1 0.420
 Intensified 1.73 (1.18–2.54)   2.28 (0.96–5.42)   0.88 (0.67–1.17)   1.55 (0.54–4.45)  
EBV serostatus,       
 Other 1 0.046 1 0.038   
D−/R+ 1.58 (1.01–2.46)   2.85 (1.06–7.670      
CMV serostatus       
 Other    1 0.420 1 0.051
 D−/R+      0.79 (0.44–1.41)   4.54 (0.99–20.78)  
ATG dose,
 7.5 mg/kg 1 < 0.001 1 0.065 1 0.013 1 0.050
 10.0 mg/kg 2.02 (1.37–2.97)   2.45 (0.95–6.33)   1.31 (1.06–1.62)   3.65 (1.00–13.32)  
  1. HR hazard ratio